OBJECTIVES: Despite antiretroviral therapy (ART), there is an unmet need for therapies to mitigate immune activation in HIV infection. The goal of this study is to determine whether the apoA-I mimetics 6F and 4F attenuate macrophage activation in chronic HIV. DESIGN: Preclinical assessment of the in-vivo impact of Tg6F and the ex-vivo impact of apoA-I mimetics on biomarkers of immune activation and gut barrier dysfunction in treated HIV. METHODS: We used two humanized murine models of HIV infection to determine the impact of oral Tg6F with ART (HIV+ART+Tg6F+) on innate immune activation (plasma human sCD14, sCD163) and gut barrier dysfunction [murine I-FABP, endotoxin (LPS), LPS-binding protein (LBP), murine sCD14]. We also used gut explants from 10 uninfected and 10 HIV-infected men on potent ART and no morbidity, to determine the impact of ex-vivo treatment with 4F for 72 h on secretion of sCD14, sCD163, and I-FABP from gut explants. RESULTS: When compared with mice treated with ART alone (HIV+ART+), HIV+ART+Tg6F+ mice attenuated macrophage activation (h-sCD14, h-sCD163), gut barrier dysfunction (m-IFABP, LPS, LBP, and m-sCD14), plasma and gut tissue oxidized lipoproteins. The results were consistent with independent mouse models and ART regimens. Both 4F and 6F attenuated shedding of I-FABP and sCD14 from gut explants from HIV-infected and uninfected participants. CONCLUSION: Given that gut barrier dysfunction and macrophage activation are contributors to comorbidities like cardiovascular disease in HIV, apoA-I mimetics should be tested as therapy for morbidity in chronic treated HIV.
OBJECTIVES: Despite antiretroviral therapy (ART), there is an unmet need for therapies to mitigate immune activation in HIV infection. The goal of this study is to determine whether the apoA-I mimetics 6F and 4F attenuate macrophage activation in chronic HIV. DESIGN: Preclinical assessment of the in-vivo impact of Tg6F and the ex-vivo impact of apoA-I mimetics on biomarkers of immune activation and gut barrier dysfunction in treated HIV. METHODS: We used two humanized murine models of HIV infection to determine the impact of oral Tg6F with ART (HIV+ART+Tg6F+) on innate immune activation (plasma human sCD14, sCD163) and gut barrier dysfunction [murine I-FABP, endotoxin (LPS), LPS-binding protein (LBP), murine sCD14]. We also used gut explants from 10 uninfected and 10 HIV-infected men on potent ART and no morbidity, to determine the impact of ex-vivo treatment with 4F for 72 h on secretion of sCD14, sCD163, and I-FABP from gut explants. RESULTS: When compared with mice treated with ART alone (HIV+ART+), HIV+ART+Tg6F+ mice attenuated macrophage activation (h-sCD14, h-sCD163), gut barrier dysfunction (m-IFABP, LPS, LBP, and m-sCD14), plasma and gut tissue oxidized lipoproteins. The results were consistent with independent mouse models and ART regimens. Both 4F and 6F attenuated shedding of I-FABP and sCD14 from gut explants from HIV-infected and uninfected participants. CONCLUSION: Given that gut barrier dysfunction and macrophage activation are contributors to comorbidities like cardiovascular disease in HIV, apoA-I mimetics should be tested as therapy for morbidity in chronic treated HIV.
Authors: Mary Jane Potash; Wei Chao; Galina Bentsman; Nicolae Paris; Manisha Saini; Jadwiga Nitkiewicz; Paula Belem; Leroy Sharer; Andrew I Brooks; David J Volsky Journal: Proc Natl Acad Sci U S A Date: 2005-02-23 Impact factor: 11.205
Authors: Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek Journal: J Infect Dis Date: 2011-01-20 Impact factor: 5.226
Authors: Catherine E Watson; Nicole Weissbach; Lise Kjems; Surya Ayalasomayajula; Yiming Zhang; Ih Chang; Mohamad Navab; Susan Hama; Greg Hough; Srinivasa T Reddy; Daniel Soffer; Daniel J Rader; Alan M Fogelman; Alison Schecter Journal: J Lipid Res Date: 2010-11-10 Impact factor: 5.922
Authors: Mohamad Navab; Ishaiahu Shechter; G M Anantharamaiah; Srinivasa T Reddy; Brian J Van Lenten; Alan M Fogelman Journal: Arterioscler Thromb Vasc Biol Date: 2009-07-16 Impact factor: 8.311
Authors: Ursula Hofer; Erika Schlaepfer; Stefan Baenziger; Marc Nischang; Stephan Regenass; Reto Schwendener; Werner Kempf; David Nadal; Roberto F Speck Journal: PLoS Pathog Date: 2010-04-29 Impact factor: 6.823
Authors: Arnab Chattopadhyay; Xinying Yang; Pallavi Mukherjee; Dawoud Sulaiman; Hannah R Fogelman; Victor Grijalva; Steven Dubinett; Tonya C Wasler; Manash K Paul; Ramin Salehi-Rad; Julia J Mack; M Luisa Iruela-Arispe; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy Journal: Sci Rep Date: 2018-06-13 Impact factor: 4.379
Authors: Maria Daskou; William Mu; Madhav Sharma; Hariclea Vasilopoulos; Rachel Heymans; Eleni Ritou; Valerie Rezek; Philip Hamid; Athanasios Kossyvakis; Shubhendu Sen Roy; Victor Grijalva; Arnab Chattopadhyay; Scott G Kitchen; Alan M Fogelman; Srinivasa T Reddy; Theodoros Kelesidis Journal: PLoS Pathog Date: 2022-01-07 Impact factor: 6.823
Authors: Pallavi Mukherjee; Arnab Chattopadhyay; Victor Grijalva; Nasrin Dorreh; Venu Lagishetty; Jonathan P Jacobs; Bethan L Clifford; Thomas Vallim; Julia J Mack; Mohamad Navab; Srinivasa T Reddy; Alan M Fogelman Journal: J Lipid Res Date: 2021-11-20 Impact factor: 5.922
Authors: M Daskou; M Sharma; W Mu; R Heymans; E Ritou; V Rezek; P Hamid; A Kossyvakis; S Sen Roy; V Grijalva; A Chattopadhyay; J Papesh; D Meriwether; S G Kitchen; A M Fogelman; S T Reddy; T Kelesidis Journal: Metabolism Date: 2021-09-09 Impact factor: 8.694